Introduction. My last look at Voyager Therapeutics, Inc. (NASDAQ:VYGR) was in September 2023.Voyager was developing a one-and-done Alzheimer’s gene therapy treatment. It was still seeking an IND ...

Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $6.47 million during the quarter, compared to analyst estimates of $13.55 million.

LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today ...

Voyager Therapeutics Inc (NASDAQ: VYGR). shares have tumbled to a 52-week low, touching down at $2.71, as the biotechnology firm faces a challenging period marked by investor concerns.

Voyager Therapeutics Inc has a consensus price target of $16 based on the ratings of 12 analysts. The high is $30 issued by HC Wainwright & Co. on April 8, 2025.The low is $7 issued by Wedbush on ...

Voyager Therapeutics, Inc.: Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und . FNRD-2.627.0 ...

Fintel reports that on December 2, 2024, Citigroup initiated coverage of Voyager Therapeutics (NasdaqGS:VYGR) with a Buy recommendation. Analyst Price Forecast Suggests 156.07% Upside As of ...

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes ...

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company’s lead product candidate is VY7523, an anti-tau antibody ...

An on-demand webcast of the pre-recorded fireside chat will be available and may be accessed from the Investors section of Voyager's website at ir.voyagertherapeutics.com starting at 7:00 a.m. ET on ...